Application of endoplasmic reticulum stress inhibitor in preparation of medicine for eliminating or relieving hepatotoxicity caused by pezopanib

Through endoplasmic reticulum stress inhibitors and ornithine metabolism regulators, the hepatotoxicity problem caused by pezopanib was solved, which significantly alleviated hepatocellular apoptosis and autophagy, and provided a new direction for hepatotoxic intervention.

CN118987216APending Publication Date: 2024-11-22HANGZHOU YIBAI HEALTH MANAGEMENT CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410984768.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In clinical applications, pezopanib is often accompanied by high incidence of liver toxicity, and the lack of effective intervention strategies has led to hindering its clinical application and the mechanism of hepatotoxicity is not completely clear.

Method used

Use endoplasmic reticulum stress inhibitors such as 4-PBA, silencing agents of HSPA5, arginase inhibitors nor-NOHA and L-ornithine metabolic regulators to alleviate or eliminate perazole Hepatotoxicity caused by panibide is regulated by regulating the PI3K/Akt/mTOR signaling pathway and ornithine metabolism pathway.

Benefits of technology

Significantly attenuate the apoptosis and autophagy of hepatocytes mediated by pezopanib, reverse the hepatotoxicity caused by it, and provide a potential intervention target and treatment direction, providing a theoretical basis for the development of anti-toxic drugs for pezopanib hepatotoxicity. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004957064670000052
    Figure BDA0004957064670000052
  • Figure BDA0004957064670000062
    Figure BDA0004957064670000062
  • Figure BDA0004957064670000071
    Figure BDA0004957064670000071
Patent Text Reader

Abstract

The invention discloses an application of an endoplasmic reticulum stress inhibitor in preparation of a medicine for eliminating or relieving hepatotoxicity caused by pezopanib. According to the application disclosed by the invention, the endoplasmic reticulum stress inhibitor 4-PBA and the silent HSPA5 can be used for weakening the apoptosis level of pezopanib mediated L02 cells, remarkably inhibiting the protein expression level of endoplasmic reticulum stress related proteins ATF4, ATF6 and CHOP as well as autophagic proteins LC3 and Beclin-1 and further activating a PI3K / Akt / mTOR signal channel; meanwhile, the L-ornithine is supplemented in vitro, so that the pzoparib-mediated hepatocyte apoptosis and autophagy can be partially reversed, and the L-ornithine can be applied to preparation of medicines for eliminating or relieving hepatotoxicity caused by pzoparib.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to application of an endoplasmic reticulum stress inhibitor in the preparation of a medicament for eliminating or alleviating hepatotoxicity caused by pazopanib. Background Art

[0002] Pazopanib is a tyrosine kinase inhibitor (TKI), commonly used in the first-line treatment of patients with advanced clear cell renal cell carcinoma (ccRCC) and the treatment of advanced RCC patients who have received cytokine therapy. Compared with other TKI targeted monotherapy drugs such as sunitinib and cabozantinib, pazopanib shows good efficacy, safety and economy in the intervention of metastatic renal cancer, and significantly improves the quality of life of patients with renal cancer. Unfortunately, the clinical application of pazopanib is often accompanied by high incidence and varying degrees of liver toxicity. Due to the lack of effective intervention strategies, liver toxicity has become a huge obstacle to the clinical application of pazopanib. However, the specific mechanism of pazopanib-induced adverse liver toxicity is not fully understood. Summary of the invention

[0003] The purpose of the present invention is to overcome the defects of the prior art and provide the use of an endoplasmic reticulum stress inhibitor in the preparation of a drug for eliminating or alleviating the hepatotoxicity caused by pazopanib.

[0004] To achieve the above object, the present invention adopts the following technical solutions:

[0005] Use of an endoplasmic reticulum stress inhibitor in the preparation of a drug for eliminating or alleviating hepatotoxicity caused by pazopanib.

[0006] Preferably, the endoplasmic reticulum stress inhibitor comprises 4-PBA.

[0007] The present invention also provides the use of an endoplasmic reticulum stress marker protein silencing agent in the preparation of a drug for eliminating or alleviating the hepatotoxicity caused by pazopanib.

[0008] Preferably, the endoplasmic reticulum stress marker protein includes the endoplasmic reticulum stress marker protein HSPA5.

[0009] The present invention also provides the use of L-ornithine metabolic regulator in the preparation of a medicine for eliminating or alleviating the hepatotoxicity caused by pazopanib.

[0010] Preferably, the L-ornithine metabolism regulator comprises the arginase inhibitor nor-NOHA.

[0011] The present invention also provides the use of an arginase inhibitor nor-NOHA and an HSPA5 silencing agent in the preparation of a drug for eliminating or alleviating the hepatotoxicity caused by pazopanib.

[0012] The present invention also provides the use of L-ornithine supplement in preparing a medicine for eliminating or alleviating the hepatotoxicity caused by pazopanib.

[0013] The present invention also provides the use of the endoplasmic reticulum stress inhibitor and pazopanib in preparing a drug for treating renal cell carcinoma.

[0014] The present invention also provides the use of an endoplasmic reticulum stress marker protein silencing agent and pazopanib in the preparation of a drug for treating renal cell carcinoma.

[0015] The beneficial effects of the present invention compared with the prior art are:

[0016] (1) The endoplasmic reticulum stress inhibitor 4-PBA and silencing of HSPA5 in the present invention can weaken the apoptosis level of L02 cells mediated by pazopanib, and significantly inhibit the expression levels of endoplasmic reticulum stress-related proteins ATF4, ATF6 and CHOP and autophagy proteins LC3 and Beclin-1, and further activate the PI3K / Akt / mTOR signaling pathway. At the same time, in vitro supplementation of L-ornithine can partially reverse pazopanib-mediated hepatocyte apoptosis and autophagy, and can be used in the preparation of drugs for eliminating or reducing hepatotoxicity caused by pazopanib.

[0017] (2) Since the ornithine cycle pathway for the synthesis of urea in the liver plays a pivotal role in the detoxification of ammonia when the blood ammonia concentration increases when liver function is reduced or liver dysfunction occurs, and at the same time, ornithine is an intermediate metabolite of arginine biosynthesis, the present invention uses the arginase inhibitor nor-NOHA. Based on the established L02 cell model induced by silencing HSPA5 and pazopanib, the study found that nor-NOHA can significantly reverse the inhibition of hepatocyte apoptosis mediated by silencing HSPA5, the increase in autophagy and the activation level of the PI3K / Akt / mTOR signaling pathway. Therefore, L-ornithine and targeted intervention of HSPA5 are potential effective drugs and targets for intervention of pazopanib hepatotoxicity. Targeted inhibition of HSPA5 and regulation of ornithine metabolic pathways can reverse pazopanib-induced liver damage in mice.

[0018] (3) The present invention provides a molecular basis for elucidating the hepatotoxic mechanism of pazopanib and a theoretical basis for exploring new drug targets for treating pazopanib-induced liver injury, thereby providing a direction for the research and development of pazopanib antidote drugs.

[0019] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The effect of gradient concentration of pazopanib on the viability of L02 hepatocytes ( n=6) (Note: Compared with the DMSO solvent control group, ▲ P<0.05, ▲▲ P<0.01);

[0021] Figure 2 Effects of pazopanib on ROS, LDH release and SOD content levels of L02 hepatocytes (Note: A: After 20 μM pazopanib was used to treat L02 hepatocytes for 24 h, the DCFH-DA reactive oxygen species ROS fluorescent probe was used to detect the changes in ROS in L02 cells; B, C: After 20 μM pazopanib was used to treat L02 hepatocytes for 24 h, the LDH detection kit and SOD kit were used to detect the changes in cellular LDH release rate and SOD content level, respectively; Scale bar: 50 μm, 200×. ▲ P<0.05, ▲▲ P < 0.01 vs Control and DMSO group);

[0022] Figure 3 Effects of pazopanib on apoptosis of human L02 hepatocytes (Note: A: After 20 μM pazopanib was applied to L02 hepatocytes for 24 h, Tunel staining was used to detect the apoptosis level of L02 hepatocytes; Scale bar: 50 μm, 200×; B: After 20 μM pazopanib was applied to L02 hepatocytes for 24 h, flow cytometry was used to detect the apoptosis level of L02 hepatocytes. ▲▲ P < 0.01. Control and DMSO groups);

[0023] Figure 4 Effects of pazopanib on mitochondrial membrane potential and function of L02 cells (Note: A: After 20 μM pazopanib acted on L02 hepatocytes for 24 h, flow cytometry was used to detect the changes in mitochondrial membrane potential in L02 cells of each group; B: After 20 μM pazopanib acted on L02 hepatocytes for 24 h, real-time fluorescence quantitative PCR was used to detect the mRNA expression level of COX I in L02 cells of each group; ▲▲ P < 0.01. Control and DMSO groups);

[0024] Figure 5 The anatomical diagrams of the kidney, heart, and liver of mice in each group and the changes in the organ indexes of mice;

[0025] Figure 6 The liver tissue pathological examination of mice gavaged with pazopanib for 8 weeks (Note: Scale bar: 100 μm, 200×; 50 μm, 400×);

[0026] Figure 7The levels of inflammatory factors TNF-α, IL-1β, IL-6, CXCL1, MCP-1, and MPO in mouse serum ( n=6) (Note: Compared with the Control group, ▲ P<0.05, ▲▲ P<0.01);

[0027] Figure 8 Effects of pazopanib on apoptosis and ultrastructure of mouse liver tissue cells (Note: A: Tunel fluorescence staining to observe apoptosis in mouse liver tissue; Scale bars: 100μm, 100×; 50μm, 200×; B: Transmission electron microscopy to observe mitochondrial and endoplasmic reticulum structures in mouse liver tissue);

[0028] Fig. 9 This is the principal component analysis of mouse liver genes in the high-dose pazopanib group and the control group (Note: After the samples are analyzed by dimensionality reduction, there are relative coordinate points on the principal components; the distance between each sample point represents the distance between samples. The closer the distance, the higher the similarity between samples, indicating that the biological repetition between samples is better; the horizontal axis represents the contribution of principal component 1 (PC1) in the two-dimensional graph to distinguishing samples, and the vertical axis represents the contribution of principal component 2 (PC2) in the two-dimensional graph to distinguishing samples);

[0029] Fig.10 TPM box plot of gene expression levels in the control group (A) and pazopanib group (B) (Note: the horizontal axis is the name of the control group (A) and pazopanib group (B); the vertical axis is the logarithm of the expression level with base 10. Each color in the figure represents a sample / group, and the horizontal line in the figure represents the median of gene expression in each group)

[0030] Fig.11 It is a differential gene volcano map (Note: the horizontal axis is the fold change value of the gene expression difference between the two groups, that is, the value obtained by dividing the expression of the treatment group by the expression of the control group; the vertical axis is the statistical test value of the difference in gene expression change, that is, Padjust; the smaller the P value, the more significant the expression difference, and the values ​​of the horizontal and vertical axes are logarithmically processed; each point in the figure represents a specific differential gene, and the default red point represents a significantly up-regulated differential gene, the green point represents a significantly down-regulated gene, and the gray point represents a gene with no statistical difference; after mapping all the genes, it can be seen that the points on the left are genes with differential expression down-regulated, and the points on the right are genes with differential expression up-regulated, and the points closer to the sides and the top are more significant in terms of expression difference);

[0031] Fig.12It is a heat map of differential gene clustering (Note: each column in the figure represents a sample, each row represents a gene, and the color in the figure represents the expression level of the gene in the sample. By default, red represents a higher expression level of the gene in the sample, and blue represents a lower expression level. The specific expression level change trend is marked by the number under the color bar in the upper right corner; the left side is the gene clustering dendrogram, and the right side is the gene name. The closer the two gene branches are, the closer their expression levels are; the top is the sample clustering dendrogram, and the bottom is the sample name. The closer the two sample branches are, the closer the expression patterns of all genes in the two samples are, that is, the closer the gene expression level change trends are).

[0032] Fig.13 The top 20 entries of GO enrichment scores of liver differential genes in pazopanib-mediated mouse liver injury (Note: the vertical axis represents GO term, the horizontal axis represents Rich factor [the ratio of the number of genes enriched in the GO term (Sample number) to the number of annotated genes (Background number). The larger the Rich factor, the greater the degree of enrichment], the size of the point represents the number of genes in this GO term, and the color of the point corresponds to different Padjust ranges);

[0033] Fig.14 The top 20 entries of the KEGG pathway score of liver differential genes in pazopanib-mediated mouse liver injury (Note: the vertical axis represents the name of the KEGG pathway, the horizontal axis represents the Rich factor [the ratio of the number of genes enriched in the KEGG pathway (Sample number) to the number of annotated genes (Background number). The larger the Rich factor, the greater the degree of enrichment], the size of the point represents the number of genes in this KEGG pathway, and the color of the point corresponds to different Padjust ranges);

[0034] Fig.15 PPI network of significantly differentially expressed genes (Note: nodes represent genes, edges represent interactions between two genes; the size of a node is proportional to the degree of the node, that is, the more edges connected to the node, the greater the degree of the node, indicating that the gene is more important in the network; the color depth also corresponds to the size of the interaction degree, from red to blue, indicating a gradual decrease in degree)

[0035] Fig.16 is the RSD distribution diagram of QC samples;

[0036] Fig.17 Liver samples from the high-dose pazopanib group and the control group (A) Positive ion mode (ESI +) and (B) negative ion mode (ESI - ) under PCA plot;

[0037] Fig.18 OPLS-DA diagrams of liver samples in the high-dose pazopanib group and the control group (Note: A: PLS-DA analysis score diagram in positive ion mode; B: PLS-DA analysis score diagram in negative ion mode; C: permutation test diagram in positive ion mode; D: permutation test diagram in negative ion mode);

[0038] Fig.19 The differential metabolites between the liver samples of the high-dose pazopanib group and the control group (Note: A: Volcano plot of the high-dose pazopanib group and the control group in positive ion mode; B: Volcano plot of the high-dose pazopanib group and the control group in negative ion mode; Metabolites that meet VIP>1 and p-value<0.05 are indicated by red for upregulation and blue for downregulation. Non-significantly different metabolites are indicated in gray; C: Cluster heat map of the top 30 differential metabolites and VIP bar chart. The left side is the metabolite clustering dendrogram. The closer the branches are, the closer the expression patterns of all metabolites in the sample are; each column represents a sample, and the sample name is below; each row represents a metabolite, and the color represents the relative expression of the metabolite in the group of samples. The right side is the metabolite VIP bar chart. The length of the bar represents the contribution of the metabolite to the difference between the two groups. The default value is not less than 1. The larger the value, the greater the difference between the two groups. The color of the bar indicates the significance of the difference between the metabolites in the two groups of samples, that is, the P-value. The smaller the P-value, the -log10 (P-value) The larger the value, the darker the color. On the right, * represents P < 0.05, ** represents P < 0.01, and *** represents P < 0.001);

[0039] Fig. 20 KEGG enrichment bubble diagram of differential metabolites (Note: the horizontal axis is the enrichment significance P value. The smaller the P value, the more statistically significant it is. Generally, a P value less than 0.05 is considered to be a significant enrichment item; the vertical axis is the KEGG pathway; the size of the bubble in the figure represents the number of compounds enriched in the metabolic set in the pathway)

[0040] Fig.21 Spearman correlation analysis between differential metabolites and key genes (Note: the horizontal axis and vertical axis represent metabolites and key genes, respectively; the redder or greener the color corresponding to the gene and metabolite, the stronger the correlation between the gene and its corresponding metabolite, and the depth of the correlation color ranges from -1 to 1);

[0041] Fig. 22To investigate the effect of pazopanib on the expression of endoplasmic reticulum stress, apoptosis and autophagy-related proteins in mouse liver tissue (Note: AB: the effect of pazopanib treatment on the expression of HSPA5, p-IRE1α, ATF4, ATF6, p-eIF2α, and CHOP and their relative expression levels; CD: the effect of pazopanib treatment on the expression of Bax, Bcl-2, and Caspase-3 and their relative expression levels; EF: the effect of pazopanib treatment on the expression of LC3 and Beclin-1 and their relative expression levels. ▲ P<0.05, ▲▲ P<0.01, vs control group);

[0042] Fig.23 Effects of pazopanib on the morphology of endoplasmic reticulum and autophagy level in L02 cells (Note: A: Electron microscopic images of endoplasmic reticulum in L02 cells of each group (×10.0k, 2μm; arrows indicate endoplasmic reticulum); B: Electron microscopic images of autophagosomes in L02 cells of each group (×10.0k, 2μm; ×25.0k, 500nm; red boxes indicate autophagosomes).)

[0043] Fig.24 Pazopanib promotes the expression of endoplasmic reticulum stress-related proteins in L02 hepatocytes (Note: The effect and relative expression of HSPA5, p-IRE1α, ATF4, ATF6, p-eIF2α, and CHOP in L02 hepatocytes treated with AB Pazopanib. ▲ P<0.05, ▲▲ P<0.01, vs blank control group and solvent control group);

[0044] Fig.25 Pazopanib promotes the expression of autophagy-related proteins in L02 hepatocytes and downregulates the levels of PI3K / AKT / mTOR pathway (Note: AB The effect of pazopanib on the expression of LC3 and Beclin-1 in L02 hepatocytes and their relative expression levels. BC The effect of pazopanib on the expression of p-PI3K, PI3K, p-AKT, AKT, p-mTOR, and mTOR in L02 hepatocytes and their relative expression levels. ▲ P<0.05, ▲▲ P<0.01, vs blank control group and solvent control group)

[0045] Fig.26PBA and silencing HSPA5 inhibited pazopanib-mediated apoptosis of L02 cells (Note: A: qPCR detection of the statistical results of the relative mRNA expression of HSPA5 in L02 cells transfected with siRNAHSPA5; B: Western blot detection of the statistical results of the relative protein expression of HSPA5 in L02 cells transfected with siRNAHSPA5; C: Flow cytometry detection of the apoptosis rate of L02 cells transfected with 4-PBA and siRNAHSPA5. ▲▲ P < 0.01, vs control, siRNAHSPA5_NC or 4-PBA group; ** P<0.01, vs Pazopanib group; ## P<0.01, vs Pazopanib+siRNAHSPA5_NC group)

[0046] Fig. 27 4-PBA and silencing HSPA5 reduce the expression of endoplasmic reticulum stress-related proteins induced by pazopanib (Note: ▲▲ P < 0.01, vs control or 4-PBA group; * P<0.05, ** P<0.01, vs Pazopanib group; # P<0.05, ## P<0.01, vsPazopanib+siRNAHSPA5_NC group)

[0047] Fig.28 4-PBA and silencing HSPA5 inhibited the autophagy level induced by pazopanib in L02 cells and enhanced the expression of PI3K / Akt / mTOR pathway proteins (Note: ▲▲ P < 0.01, vs control or 4-PBA group; * P<0.05, ** P<0.01, vs Pazopanib group; # P<0.05, ## P < 0.01, vs Pazopanib + siRNA HSPA5_NC group);

[0048] Fig.29Effects of L-ornithine and nor-NOHA on apoptosis, autophagy and PI3K / Akt / mTOR pathway of L02 cells induced by pazopanib (Note: A: Flow cytometry was used to detect the effects of L-ornithine supplementation and inhibition of ornithine metabolic pathway on apoptosis of L02 cells induced by pazopanib; B: Western blot was used to detect the effects of L-ornithine supplementation and inhibition of ornithine metabolic pathway on endoplasmic reticulum stress, autophagy, apoptosis and the expression levels of proteins related to PI3K / Akt / mTOR pathway of L02 cells induced by pazopanib. ▲▲ P < 0.01, vs control or L-ornithine group; ** P<0.01, vs Pazopanib group; ## P<0.01, vs Pazopanib+siRNAHSPA5 group). DETAILED DESCRIPTION

[0049] Example 1

[0050] Effects of pazopanib on inflammatory response and oxidative stress-induced hepatotoxicity

[0051] In this example, the pazopanib liver injury model of L02 hepatocytes and C57BL / 6 mice was constructed to explore the role of pazopanib in inducing hepatocellular toxicity and liver injury in mice, laying a theoretical foundation for the study of the molecular mechanism related to pazopanib liver toxicity.

[0052] Experimental cell lines:

[0053] In this embodiment, the normal human liver cell line L02 (iCell-h054) was purchased from Synbio (Shanghai) Biotechnology Co., Ltd. The L02 cells were cultured in an incubator at a constant temperature of 37°C and a CO2 concentration of 5%. The CuSO4 aqueous solution in the water tray was added and replaced every 2 weeks to maintain a certain humidity in the incubator.

[0054] Experimental Animals:

[0055] In this example, 72 C67BL / 6J mice, half male and half female, 6 weeks old (about 18-22g), were provided by Spike (Beijing) Biotechnology Co., Ltd., Animal Production License No.: SCXK (Beijing) 2019-0010. All animals in this experiment were raised in the Experimental Animal Research Center of Zhejiang Yingyang Pharmaceutical Research and Development Center, SPF-level environment, 2-3 per cage, constant temperature (22±2°C), constant humidity (55±5%), 12 hours daytime-12 hours nighttime, unlimited drinking water and food, and fed with ordinary feed (70% carbohydrates, 20% protein and 10% fat).

[0056] Experimental drugs

[0057] In this example, the small molecule kinase inhibitor pazopanib was purchased from Dalian Meilun Biotechnology Co., Ltd. (MB1299).

[0058] The experimental methods and results are as follows:

[0059] 1. L02 cell hepatotoxicity modeling:

[0060] Pazopanib was added to the normal culture medium to make the final concentration of pazopanib in the cell culture medium 0, 2, 5, 10, 15, 20, 40, 80 μmol / L, and 0.1% DMSO solution was used as the control group. After different concentrations of pazopanib were used to intervene in L02 cells for 24h, 48h and 72h, the cell viability was detected by Cell counting kit-8 (CCK-8), and the optimal concentration and time of pazopanib on the hepatotoxicity of L02 hepatocytes were determined according to the CCK-8 results.

[0061] From Table 1 and Figure 1 It can be seen that when the concentration of pazopanib is between 0μM and 15μM, the cell viability gradually decreases, which is inversely proportional to the concentration; when the concentration is between 15μM and 80μM, the drug precipitates and the cell viability increases. Taking all factors into consideration, it is planned to use 20μM pazopanib to act on L02 hepatocytes for 24h as the subsequent cell experimental conditions.

[0062] Table 1 Effects of different concentrations of pazopanib on cell viability of L02 hepatocytes ( n=6)

[0063]

[0064] Note: Compared with the 1 / 1000 DMSO solvent control group, ▲ P<0.05, ▲▲ P<0.01.

[0065] 2. Intervention of optimal concentration of pazopanib on L02 cells:

[0066] L02 cells were divided into blank control group, solvent control group and pazopanib group. L02 cells were treated for 24 h and the cells were collected. Reactive oxygen species (ROS), lactate dehydrogenase (LDH) and superoxide dismutase (SOD) levels in cells of each group were detected by reactive oxygen species detection kit, lactate dehydrogenase cytotoxicity detection kit and CuZn / Mn-SOD activity detection kit respectively. Flow cytometry was used to detect the mitochondrial membrane potential level after pazopanib treatment in L02 cells. Flow cytometry and TUNEL were used to detect the apoptosis of L02 cells after pazopanib treatment. RT-qPCR was used to detect the mRNA expression level of cytochrome C oxidase Ⅰ (COX Ⅰ), an important mitochondrial energy metabolism molecule, after pazopanib treatment in L02 cells.

[0067] result:

[0068] (1) Pazopanib significantly increased the levels of ROS and LDH release in human liver L02 cells and reduced the level of cellular SOD content

[0069] Depend on Figure 2 As shown in Figure A, compared with the blank control group (Control group), there was no significant difference in the fluorescence intensity of ROS in the solvent control group (DMSO group) L02 cells, indicating that the DMSO concentration used in this experiment had no significant damaging effect on L02 cells. Compared with the solvent control group, the fluorescence intensity of ROS in the pazopanib group (Pazopanib group) L02 cells was significantly enhanced, indicating that 20μM pazopanib significantly increased the ROS activity level in L02 cells. In addition, it was observed that 20μM pazopanib significantly increased the release of LDH in L02 cells and effectively inhibited the cellular SOD content level ( Figure 2 B and C).

[0070] (2) Pazopanib significantly induces apoptosis in human L02 hepatocytes

[0071] Tunel staining and flow cytometry analysis were performed on L02 cells treated with pazopanib. The results showed that compared with the blank control group (Control group), there was no significant difference in the fluorescence intensity of Tunel in the solvent control group (DMSO group) L02 cells. Compared with the solvent control group (DMSO group), the fluorescence intensity of L02 hepatocytes in the pazopanib group (Pazopanib group) was significantly increased (see Figure 3 At the same time, flow cytometry analysis results showed that pazopanib significantly increased the apoptosis level of L02 hepatocytes (see Figure 3 (middle B).

[0072] (3) Pazopanib significantly reduced mitochondrial membrane potential and function in L02 cells

[0073] The process of apoptosis is often accompanied by a decrease in mitochondrial membrane potential, which is considered to be one of the most obvious characteristics of apoptosis. Therefore, this example investigates whether the apoptosis of liver L02 cells induced by pazopanib is accompanied by changes in mitochondrial function. L02 cells were treated with 20 μM pazopanib for 24 hours, and then the changes in mitochondrial membrane potential of L02 cells were detected by JC-1 staining combined with flow cytometry. The results are shown in Figure 2. Figure 4 As shown in A, 20 μM pazopanib can significantly cause a decrease in mitochondrial membrane potential of L02 cells after 24 hours of action. In addition, the expression level of COX I mRNA, the core subunit of mitochondrial respiratory chain complexes I, III, IV, and V, was detected by real-time fluorescence quantitative PCR. The results showed that compared with the blank control group (Control group) and the solvent control group (DMSO group), the mRNA expression level of COX I in the pazopanib group (Pazopanib group) was significantly reduced, indicating that pazopanib may inhibit the expression of core subunits of the respiratory chain complex, leading to the occurrence of apoptosis in L02 cells (see Figure 4 (middle B).

[0074] 3. To evaluate the in vivo hepatotoxicity of pazopanib, 72 C57BL / 6J mice were adaptively fed for 1 week and then randomly divided into a normal group and pazopanib low, medium and high groups, 18 mice each, 9 males and 9 females. The pazopanib low, medium and high groups were intragastrically administered with 150, 300 and 500 mg / kg pazopanib, respectively, and the normal group was intragastrically administered with an equal amount of normal saline. After 2, 4, and 8 weeks of intragastric administration, 3 male and 3 female mice were randomly selected from each group at each time point and killed for specimen collection: the weights of kidney, heart, and liver of mice in each group were measured using an electronic balance, and the changes in the corresponding organ indexes were calculated; the contents of ALT, AST, TBIL, and ALB, the biochemical indicators of liver function in mice, were detected by an automatic biochemical detector; the levels of inflammatory-related factors TNF-α, IL-1β, IL-6, CXCL l, MCP-1, and MPO in the serum of mice after pazopanib treatment were detected by ELISA kits; the pathological morphological changes of liver tissues of mice in each group were observed by HE staining; the cell apoptosis in the liver tissues of mice was observed by Tunel staining; and the ultrastructural changes of the liver tissues of mice were observed by transmission electron microscopy.

[0075] result:

[0076] (1) Effects of pazopanib on liver function in mice

[0077] The clinical dosage of pazopanib is 800 mg per day, and the administration time and drug dosage are important factors affecting whether the drug liver injury model can be successfully established. Therefore, the concentration and administration cycle of pazopanib were increased, and 150, 300, and 500 mg / kg (equivalent to 1.2, 2.5, and 4 times the clinical dose, respectively) of pazopanib was administered orally once a day to C57BL / 6J mice for 2 weeks, 4 weeks, and 8 weeks. Then, the mouse serum was taken to detect liver function biochemical indicators such as ALT and AST to preliminarily determine the degree of liver injury, and liver tissue was collected for subsequent pathological and molecular biological testing. The results are shown in Table 2. In the second and fourth weeks, compared with the control group, there were no significant changes in the blood liver function biochemical indexes ALT, AST, TBIL, and ALB of mice in the low-dose group, medium-dose group, and high-dose group. In the eighth week, compared with the control group, the blood liver function biochemical indexes ALT, AST, TBIL, and ALB of mice in the medium-dose group and high-dose group were significantly increased, indicating that the liver function of mice was significantly damaged in the eighth week after oral administration of pazopanib.

[0078] Table 2 Changes in the levels of ALT, AST, TBIL and ALB in the blood biochemical indicators of liver function in mice

[0079]

[0080] Note: Compared with the control group, ▲ P<0.05, ▲▲ P<0.01.

[0081] (2) Effects of pazopanib on kidney, heart, and liver indices in mice

[0082] As can be seen from the above, pazopanib gavage mice showed obvious liver toxicity at the eighth week. Therefore, the tissue materials of mice at the eighth week were selected for subsequent testing. It is worth noting that, as shown in Table 3 and Figure 5 As shown, there were no significant differences in body weight, cardiac index, liver index and kidney index in the pazopanib group compared with the control group.

[0083] Table 3 Changes in organ indexes of mice in each group (χ±s, n=6)

[0084]

[0085] Note: Compared with the control group, ▲ P<0.05, ▲▲ P<0.01.

[0086] (3) Effects of pazopanib on pathological changes in mouse liver tissue

[0087] HE staining is one of the most common tissue section staining techniques, which is used to observe and analyze the structure and morphology of tissues or cells under a microscope. This example further uses HE staining to conduct histopathological morphology on paraffin sections of the liver of mice after oral administration of 500 mg / kg pazopanib for 8 weeks. The results of H&E staining showed that the liver tissue morphology and structure of mice in the normal control group were intact, the morphology and structure of the vascular system were normal, the hepatocytes were neatly arranged, and there was no inflammatory cell infiltration in the liver tissue; the liver tissue of mice in the pazopanib group showed local cell vacuolar necrosis and hydropic degeneration, extensive turbid swelling of hepatocytes, disordered arrangement of hepatocytes, infiltration of inflammatory cells, and obvious morphological characteristics of hepatocyte apoptosis with pyknosis and dark staining of nuclei and blurred interspaces (see Figure 6 ).

[0088] (4) Pazopanib increases the expression of inflammatory factors in mouse serum

[0089] Drug toxicity induces severe apoptosis and necrosis of hepatocytes, and further promotes the release of liver damage-related molecules into the body fluid circulation. These liver damage-related molecules promote sterile inflammatory response, thereby promoting the increase in cytokine or chemokine formation. In this study, the effect of pazopanib on inflammatory response in mouse serum samples was detected. ELISA results showed that compared with the Control control group, the levels of TNF-α, IL-1β, and IL-6 in the serum of mice in the pazopanib group were significantly increased, while the levels of CXCLl, MCP-1, and MPO were significantly decreased (see Figure 7 ).

[0090] (5) Pazopanib induces apoptosis of liver cells and ultrastructural changes in mouse liver tissue

[0091] Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay (TUNEL method) and transmission electron microscopy were used to examine the paraffin sections of the liver of mice after oral administration of 500 mg / kg pazopanib for 8 weeks. TUNEL staining results showed that compared with the control group, obvious apoptosis-positive staining particles appeared in the nuclei of the liver tissues of mice in the pazopanib group (see Figure 8 At the same time, under transmission electron microscopy, the mitochondria in the liver tissue of the mice in the control group were mostly round or oval, with regular morphology and clear double membranes; the mitochondria in the liver tissue of the mice in the pazopanib group were wrinkled, with blurred double membranes, some of which were fused, and their rough endoplasmic reticulum expanded and swollen, and some of them were severely vacuolated (see Figure 8 (B).

[0092] Based on the above research findings, a pazopanib liver injury mouse model was established, and 500 mg / kg pazopanib gavage for 8 weeks was established as the modeling condition of the pazopanib mouse liver injury model. The killing effect of pazopanib on hepatocytes was further verified by the examination of model-related physiological and biochemical indicators. The TUNEL staining results also further suggested that the process of pazopanib damaging hepatocytes may be accompanied by the occurrence of cell apoptosis. The above research results showed that in the process of pazopanib-induced hepatocyte apoptosis, a significant decrease in mitochondrial membrane potential occurred, and the release of ROS and the expression level of inflammatory factors increased significantly, indicating that pazopanib may promote mitochondria-dependent apoptosis in hepatocytes, thereby damaging hepatocytes.

[0093] In summary:

[0094] (1) The cell survival rates of L02 cells were significantly different after treatment with different pazopanib concentrations for 24 h, 48 h, and 72 h. Among them, the treatment with 20 μmol / L pazopanib for 24 h had a significant effect on the survival rate of L02 cells, successfully inducing a cytotoxic injury model of L02 cells.

[0095] (2) Compared with the blank control group and solvent control group, the ROS generation, LDH release, and cell apoptosis rate of L02 cells in the 20 μmol / L pazopanib group were significantly increased, and the SOD content, mitochondrial membrane potential, and COXⅠmRNA expression level were significantly decreased.

[0096] (3) A mouse pazopanib liver injury model was established, and it was determined that 500 mg / kg oral administration for 8 weeks could be used as the modeling condition for the pazopanib mouse liver injury model. The changes in cell morphology in mouse liver tissue were verified through this model.

[0097] (4) Compared with the normal group, there were no significant differences in the body weight, cardiac index, liver index and kidney index of the mice in the pazopanib group at week 8. The blood liver function biochemical indicators ALT, AST and TBIL were significantly increased, the levels of TNF-α, IL-1β and IL-6 in the mouse serum were significantly increased, and the levels of CXCLl, MCP-1 and MPO were significantly decreased. HE staining results showed that the morphology of the liver parenchyma of the mice in the normal group was regular, the hepatocytes were arranged neatly and orderly, and the cord-like structure was clear. In the pazopanib group, obvious inflammatory cell infiltration in the liver lobules was observed, and the cells were turbid and severely condensed. The hepatocytes were arranged disorderly with narrow sinusoids. Especially after 8 weeks of pazopanib treatment, the mouse liver showed the most severe hepatocyte necrosis. Compared with the normal group, the apoptosis rate of hepatocytes in the pazopanib group was significantly increased. Transmission electron microscopy showed that the mitochondrial morphology was wrinkled and the endoplasmic reticulum cavity was significantly expanded after 8 weeks of pazopanib treatment.

[0098] Therefore, pazopanib can induce liver damage in mice and mediate the occurrence of endoplasmic reticulum stress and apoptosis.

[0099] Example 2

[0100] Correlation analysis between transcriptome and non-targeted metabolome in pazopanib-induced hepatotoxicity in mice

[0101] This example aims to conduct transcriptomic and non-targeted metabolomic studies on liver tissues of mice with pazopanib-induced hepatotoxicity and conduct joint analysis to explore the possible mechanism by which pazopanib affects mouse liver function. This example can further enrich the transcriptomic and metabolomic database resources for pazopanib hepatotoxicity research, and systematically clarify the mechanism by which pazopanib affects mouse liver function through transcriptional and metabolic differences, providing a theoretical basis and new insights for the future relief and treatment of liver damage caused by pazopanib.

[0102] 1. The test samples in this example were derived from the pazopanib-induced hepatotoxicity mouse model described in Example 1. That is, the liver tissues of mice were removed after 8 weeks of oral administration of 500 mg / kg pazopanib, quickly stored in liquid nitrogen, and stored in a -80°C ultra-low temperature refrigerator for transcriptome and non-targeted metabolome analysis.

[0103] 2. Metabolome and transcriptome joint analysis was performed by calculating the Pearson correlation coefficient using the metabolites and their associated mRNA expression levels among samples in the same group.

[0104] 3. Western blot technology was used to examine the protein expression levels of endoplasmic reticulum stress marker proteins HSPA5, p-IRE1α, IRE1α, ATF4, ATF6, p-eIF2α, eIF2α, CHOP; autophagy-related proteins LC3, Becline-1; apoptosis-related proteins Bax, Bcl-2, Caspase-3 in mouse liver tissue.

[0105] 4. Transmission electron microscopy was used to examine the endoplasmic reticulum morphology and the number of autophagic bodies in L02 cells treated with 20 μmol / L pazopanib for 24 hours.

[0106] 5. Western blot technology was used to detect the protein expression levels of HSPA5, p-IRE1α, IRE1α, ATF4, ATF6, p-eIF2α, eIF2α, CHOP in L02 cells treated with pazopanib; autophagy-related proteins LC3, Becline-1 and PI3K / AKT / mTOR signaling pathway-related targets.

[0107] result:

[0108] (1) Quality assessment of mouse liver transcriptome sequencing data using pazopanib

[0109] In this embodiment, two treatment groups were tested, each with 5 replicates, and transcriptome sequencing of 10 samples was completed. A total of 66.97Gb Clean Data was obtained after sequencing quality control detection, and Clean Data in each sample reached more than 6.49Gb, the error rate was about 0.03%, the percentage of bases with a quality of not less than 30 (Q30 bases) after filtering was 89% and above, and the GC content was about 50%, as shown in Table 4. In addition, the Clean Reads of each sample were sequenced with the specified reference genome, and the alignment rate ranged from 91.99% to 94.91%. The alignment analysis of pazopanib on mouse liver transcriptome sequencing is shown in Table 5. In general, it can be preliminarily judged that the base distribution of the library constructed in this experiment is uniform, the alignment efficiency of sequencing is good, and the selected reference genome can meet the subsequent sequencing conditions.

[0110] Table 4 Sample sequencing quality assessment statistics

[0111]

[0112] Note: (1) Sample: sample name, A: control group was given 0.5% CMC-Na solution by oral gavage every day; B: pazopanib group was given 500 mg / kg CMC-Na suspension by oral gavage every day; (2) Raw reads: total number of entries in raw sequencing data (reads, representing sequencing reads, one read is one read); (3) Raw bases: total amount of raw sequencing data (i.e., number of Raw reads multiplied by read length); (4) Clean reads: total number of entries in sequencing data after quality control; (5) Clean bases: total amount of sequencing data after quality control (i.e., number of Clean reads multiplied by read length); (6) Error rate (%): the average error rate of sequencing bases corresponding to the quality control data, generally below 0.1%; (7) Q20 (%), Q30 (%): quality assessment of sequencing data after quality control. Q20 and Q30 refer to the percentage of bases with sequencing quality above 99% and 99.9% in the total bases, respectively. Generally, Q20 is above 85% and Q30 is above 80%; (8) GC content (%): the percentage of the sum of G and C bases corresponding to the quality control data in the total bases.

[0113] Table 5 Statistics of sequence alignment analysis of pazopanib on mouse liver transcriptome sequencing

[0114]

[0115]

[0116] Note: (1) Sample: sample name, A: control group was given 0.5% CMC-Na solution by oral gavage every day; B: pazopanib group was given 500 mg / kg CMC-Na suspension by oral gavage every day; (2) Total reads: sequence statistics after filtering (i.e., Clean reads); (3) Total mapped: the number and percentage of Clean reads that can be located on the genome; (4) Multiple mapped: the number and percentage of Clean reads with multiple mapping positions on the reference sequence; (5) Unique mapped: the number and percentage of Clean reads with a unique mapping position on the reference sequence.

[0117] (2) PCA analysis of genes among samples of pazopanib-mediated mouse liver injury

[0118] The principal component analysis (PCA) method was used to perform unsupervised data dimensionality reduction analysis on all genes in the liver of mice in the high-dose pazopanib group and the control group. Fig. 9 As shown, each point represents a sample, group B (pazopanib high-dose group, n = 5) is red, group A (control group, n = 5) is blue, among which principal component 1 (PC1) can explain 28.96% of the variance, principal component 2 (PC2) can explain 13.66% of the variance, and the two groups of samples show a relative clustering trend within the group, while the groups are relatively discrete.

[0119] (3) Screening of differentially expressed genes in liver of mice induced by pazopanib

[0120] RSEM software was used to quantitatively analyze the overall expression level of genes, so as to analyze the differential expression of genes between different samples in the future. TPM was calculated and the distribution of gene expression between different samples was displayed by box plot. Fig.10 As shown, the gene dispersion of each group is low, the difference within the group is small, and the transcriptome expression of each sample is similar, indicating that the standardization results are good and suitable for the analysis of differentially expressed genes between groups.

[0121] The results of differential gene expression analysis showed that after treatment with the high-dose pazopanib group, 114 genes in the mouse liver tissue changed significantly, of which 68 genes were up-regulated and 46 genes were down-regulated, as shown in Table 6. The volcano plot is a type of scatter plot that can conveniently and intuitively display the distribution of differential gene expression between two samples. The volcano plot comparing the high-dose pazopanib group with the control group is shown in Fig.11 The cluster heat map can be used to view the differential expression of genes in different samples. The cluster heat map of differentially expressed genes between the high-dose pazopanib group and the control group in this experiment is shown in Fig.12As shown in the figure, the expression patterns of the five samples in the control group (A1, A2, A3, A4 and A5) were similar, and the expression patterns of the five samples in the high-dose pazopanib group (B1, B2, B3, B4 and B5) were similar, and the high-dose pazopanib group and the control group could be completely distinguished. This result shows that the samples in each group have good repeatability, and the differential gene cluster analysis shows that the two groups are significantly different.

[0122] Table 6 Transcriptomic analysis of differentially expressed genes in the liver of mice in the high-dose pazopanib group and the control group

[0123]

[0124]

[0125] (4) Functional enrichment analysis of differentially expressed genes in liver of mice induced by pazopanib

[0126] In order to explore the effect of pazopanib on the biological process of mouse liver, this example performed GO enrichment analysis on the differentially expressed genes obtained. In the GO term enrichment analysis of BP, CC and MF, the GO terms with more than 2 differentially expressed genes were summarized, the log10 (Padjust) value was calculated, and a bubble chart was drawn. The enrichment results are shown as follows Fig.13 As shown in the figure, the main enriched items of liver differential genes affected by pazopanib intervention in mice include: response to unfolded protein, response to endoplasmic reticulum stress, response to topologically incorrect protein, misfolded protein binding, positive regulation of nitrogen compound metabolic process, etc.

[0127] KEGG enrichment analysis was performed using the differentially expressed genes between the high-dose pazopanib group and the control group, and the 20 most significant KEGG pathways were selected for display. Fig.14As shown: the 20 most significantly enriched pathways include protein processing in endoplasmic reticulum, lipid and atherosclerosis, circadian rhythm, antigen processing and presentation, apoptosis, TNF signaling pathway, PI3K-Akt signaling pathway, autophagy, parathyroid hormone synthesis, secretion and action and other signaling pathways.

[0128] (5) PPI network analysis of differentially expressed genes in liver of mice induced by pazopanib

[0129] This example further uses the STRING protein interaction database to explore the relationship between differential gene protein interactions, and imports the differential genes in the liver tissues of mice in the high-dose pazopanib group and the control group into the STRING protein interaction database to obtain the PPI interaction network file. The file was input into the Cytoscape software for visualization and network topology analysis to obtain the node connectivity (ie, degree). The results showed that the PPI network included 55 nodes and 137 edges. The Network Analyzer analysis tool in Cytoscape was used to identify and screen the key genes (Hub genes) in the differential genes of mouse liver, and based on the degree greater than 10, HSPA5, DNAJB9, HYOU1, PPARG, HSPA1B, DDIT3, SYVN1, and IL1B were confirmed as key genes for subsequent experimental analysis. The results are shown in Figure 2. Fig.15 .

[0130] (6) RSD of pazopanib for mouse liver metabolomics QC samples

[0131] The original data includes quality control samples (Quality control, QC) and test samples. In order to better analyze the data, a series of preprocessing of the original data is required, mainly including simulation of missing values ​​(missing value recoding) and data normalization (Normalization). After data preprocessing, the impact of variations in the data that are not related to the research purpose on data analysis can be reduced, which is conducive to the screening and analysis of potential target differential metabolites. RSD is used to evaluate the stability of QC samples, so as to monitor and judge whether the instrument status is stable. For the overall data, it is generally believed that the higher the proportion of RSD less than 30% (>70%), the smaller the overall data difference, indicating that the system is more stable and the data quality is qualified. The RSD distribution diagram of pazopanib on mouse liver metabolome QC samples in this chapter is shown in the figure. Fig.16 As shown in the figure, the RSD distribution diagram shows that the instrument fluctuation is within the normal range and the data quality is high and can be used for subsequent analysis.

[0132] (7) Principal component analysis (PCA) of pazopanib on mouse liver metabolome;

[0133] PCA can clearly show the differences between and within groups of each sample. Each green dot in the figure represents a sample in the control group, and a blue triangle represents a sample in the high-dose group of pazopanib. Fig.17 As shown in the figure, in the positive and negative ion modes, the yellow prism is the QC sample, which is relatively close to the center area, indicating that the system stability is good. The 10 liver tissue samples in the high-dose pazopanib group and the control group have a good clustering trend within the group, with obvious dispersion between groups. All samples have no outliers, and the data quality is high.

[0134] (8) Partial least squares discriminant analysis (PLS-DA) of pazopanib on mouse liver metabolome

[0135] PLS-DA is a supervised discriminant analysis method and a multivariate statistical analysis method. This method uses partial least squares regression to establish a regression model between metabolite expression and sample category to predict the sample category. A PLS-DA model for each comparison group was established, and the model evaluation parameters R2 (model interpretability) and Q2 (model predictability) were obtained through cross-validation. If R2 and Q2 are closer to 1, the model is more stable and reliable. The OPLS-DA model established in this study had R2X of 0.411 and 0.37, R2Y of 0.961 and 0.937, and Q2 of 0.851 and 0.802 in positive and negative ion modes, respectively. Q2>0.5 indicates that the model has good predictive ability, indicating that the model is of good quality and has good stability and predictability. Fig.18As shown in Figure AB, in the positive and negative ion modes, the liver tissue metabolites of mice in the high-dose pazopanib group and the control group were completely separated, indicating that there were significant differences in metabolic changes between the two groups. The permutation test plot can effectively evaluate whether the PLS-DA model is overfitting. Fig.18 As shown in Figure CD, the intersection points of the regression line of point Q2 with the ordinate in both positive and negative ion modes are less than 0, which indicates that the PLS-DA model does not overfit, suggesting that the model reflects the sample characteristics well and can be used for subsequent differential metabolite identification and analysis.

[0136] (9) Identification of differential metabolites of pazopanib in mouse liver metabolome

[0137] By establishing a PLS-DA model, the variable weight value VIP was introduced to evaluate the impact of differential metabolites on the differential classification between the high-dose pazopanib group and the control group, and to explore differential metabolites that made significant contributions to the PLS-DA model. It is generally believed that metabolites with VIP>1 are recognized to have significant contributions to the establishment of the model. This study used P-value<0.05 and PLS-DAVIP>1 as the screening criteria for significant differential metabolites, and screened out 74 differential metabolites in the positive ion mode, of which 20 metabolites were increased and 54 metabolites were decreased; 41 differential metabolites in the negative ion mode, of which 17 metabolites were increased and 24 metabolites were decreased. The results are detailed in Table 7, and the overall distribution is as follows Fig.19 The cluster heat map and VIP bar chart show the expression patterns of metabolites in each sample in each difference group and the VIP values ​​of metabolites in multivariate statistical analysis and P values ​​in unidimensional statistics. The results show that there is good separation between different groups. According to the size of the VIP value, Fig.19 The top 30 differential metabolites are shown in C.

[0138] Table 7 Differential metabolites between the high-dose pazopanib group and the control group

[0139]

[0140]

[0141] (10) Metabolic pathway annotation and enrichment analysis of differential metabolites in mouse liver metabolome by pazopanib

[0142] The differential metabolites were mapped to the KEGG database, and the pathway annotation results were as follows Fig. 20The results of pathway enrichment analysis are shown in Table 8. A total of 61 pathways were enriched, of which 25 pathways were significantly enriched (P-value < 0.05), including Huntington's disease, melanogenesis, FoxO signaling pathway, nicotine addiction, spinocerebellar ataxia, long-term potentiation, cocaine addiction, alcoholism, amphetamine addiction, gap junctions, synaptic vesicle cycle, taste transmission, phenylalanine, tyrosine and tryptophan biosynthesis, glutathione metabolism, neuroactive ligand receptor interaction, aminoacyl tRNA biosynthesis, central carbon metabolism in cancer, 5-hydroxytryptamine synapse, histidine metabolism, protein digestion and absorption, choline metabolism in cancer, glycerophospholipid metabolism, arginine and proline metabolism, and phenylalanine metabolism.

[0143] Table 8 Differential metabolite pathway enrichment analysis

[0144]

[0145] Note: (1) Description: KEGG pathway name description; (2) Ratio_in_pop: The ratio of metabolites annotated to this pathway in the background metabolites. The left side of the slash is the number of KEGG compound IDs annotated to this pathway in the background metabolites. The right side of the vertical line is the number of KEGG compound IDs annotated to all pathways in the background metabolites. (3) P_value_uncorrected: The uncorrected p-value. The p-value represents whether the enriched result is statistically significant. The smaller the p-value, the more statistically significant it is. Generally, a p-value less than 0.05 is considered to be a significantly enriched item. (4) P_value_corrected: The corrected p-value.

[0146] (11) Correlation analysis between key genes and differential metabolites

[0147] In order to gain a deeper understanding of the mutual influence between differentially expressed genes and metabolites during the hepatotoxicity changes between the high-dose pazopanib group and the control group, Spearman correlation analysis was performed between the top 30 differentially expressed metabolites and key genes HSPA5, DNAJB9, HYOU1, PPARG, HSPA1B, DDIT3, SYVN1, and IL1B. The results are as follows: Figure 2.13: There are 19 metabolites positively correlated with HSPA5, HYOU1, DNAJB9, HSPA1B, DDIT3 and SYVN1, including Tanacetin, Dichotosin, Naproxen O-glucuronide, ND-Glucosylarylamine, Wogonin, Chrysophanol, 3,7-DIHYDROXYFLAVONE, Pelargonidin, THYMOQUINONE, 2,3-Dihydroxytoluene, S-methylcaptopril, Carvone oxide, 1,4-Epidioxy-p-mentha-2,8-diene, Myricanone, etc., and PPARG and IL1B are negatively correlated with the above 19 metabolites; while Taurodeoxycholic acid, N2-Succinyl-L-ornithine, Ophthalmic acid, Cinnamic acid, Sulfolithocholylglycine and other 11 metabolites, and PPARG and IL1B were positively correlated with the above 11 metabolites.

[0148] (12) Detection of protein expression related to endoplasmic reticulum stress, apoptosis and autophagy in mouse liver

[0149] In order to further verify the molecular basis of pazopanib's hepatotoxicity in mice, western blot technology was used to detect the changes in the expression of endoplasmic reticulum stress, apoptosis and autophagy-related proteins in the liver of mice induced by pazopanib. Fig. 22 As shown in the figure, compared with the control group, the expressions of endoplasmic reticulum stress marker proteins HSPA5 (GRP78), p-IRE1α, ATF4, ATF6, p-eIF2α, and CHOP proteins in the liver tissue of mice in the pazopanib group were increased ( Fig. 22 The expression of pro-apoptotic proteins Bax and Caspase-3 increased, while the expression of anti-apoptotic protein Bcl-2 decreased ( Fig. 22 CD). At the same time, Fig. 22 As shown in Figure EF, compared with the control group, the expression levels of autophagy-related proteins LC3 and Beclin-1 were significantly increased in the pazopanib group. The results showed that pazopanib may induce endoplasmic reticulum stress in mouse liver tissue and promote hepatocyte apoptosis and autophagy.

[0150] (13) Pazopanib mediates morphological changes of the endoplasmic reticulum and activation of autophagy in L02 cells

[0151] In order to clarify the effect of pazopanib on the ER morphology of L02 cells, the cells were treated with 20 μM pazopanib for 24 h, and the ER morphology was observed by transmission electron microscopy. Fig.23 As shown in Figure A, compared with the blank control group, the solvent control group had a relatively complete morphology and a relatively normal endoplasmic reticulum structure. The endoplasmic reticulum in L02 cells treated with pazopanib showed significant expansion. The results showed that pazopanib affected the changes in the morphology and structure of the endoplasmic reticulum in hepatocytes. Transmission electron microscopy can directly observe the ultrastructure of autophagosomes and is the most intuitive method for detecting autophagy. Fig.23 As shown in B, in L02 cells treated with pazopanib, the number of single-layer or double-layer autophagosome-like vesicle structures increased significantly. The results showed that pazopanib can induce the activation of autophagy in liver L02 cells and promote the formation of autophagosome structures.

[0152] (14) Pazopanib induces changes in endoplasmic reticulum stress and autophagy-related proteins in L02 cells and inhibits the expression of the PI3K / AKT / mTOR pathway

[0153] In order to further explore the effect of pazopanib on the morphological changes of the endoplasmic reticulum and the occurrence of autophagy in L02 cells, the western blot method was used to detect the endoplasmic reticulum stress and autophagy marker proteins in L02 cells. The results of Western blotting showed that compared with the blank control group and the solvent control group, the expression of HSPA5, p-IRE1α, ATF4, ATF6, p-eIF2α, CHOP, LC3, and Beclin-1 proteins in L02 cells in the pazopanib treatment group was significantly upregulated. Fig. 22 As shown in AB in 24 and AB in 24. At the same time, studies have confirmed that PI3K / AKT / mTOR-mediated autophagy has a significant regulatory effect in various liver injury models. Therefore, this chapter further uses western blot to detect the expression of p-PI3K, p-AKT and p-mTOR proteins after treating liver L02 cells with 20μM pazopanib. Fig.24 As shown in BC, compared with the blank control group and the solvent control group, the expression of p-PI3K, p-AKT and p-mTOR proteins in L02 cells in the pazopanib group was significantly reduced. The results suggest that pazopanib can inhibit the phosphorylation level of PI3K / AKT / mTOR pathway proteins.

[0154] Results: (1) RNA-seq transcriptomic analysis used |log2(Fold Change, FC)|>=1 and q-value<0.05 as the screening threshold. The results showed that oral administration of pazopanib caused significant changes in 114 genes in mouse liver tissue, of which 68 genes were upregulated and 46 genes were downregulated. All differentially expressed genes were subjected to Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, which were mainly enriched in the unfolded protein response, endoplasmic reticulum stress response signaling pathway, and lipid and atherosclerosis response regulation. A protein-protein interaction (PPI) network containing 55 nodes and 137 edges was constructed based on the differentially expressed genes. The core proteins were screened in the PPI network using the NetworkAnalyzer plug-in in the Cytoscape software, and the key genes were HSPA5, DNAJB9, HYOU1, PPARG, HSPA1B, DDIT3, SYVN1, and IL1B. (2) Based on LC-MS metabolomics analysis, the results showed that oral administration of pazopanib caused significant changes in 115 metabolites in the liver tissue of mice, of which 37 metabolites were upregulated and 78 metabolites were downregulated. Differential metabolite enrichment analysis was mainly enriched in amino acid metabolism, lipid metabolism, coenzyme factors and vitamin metabolism, carbohydrate metabolism, nucleotide metabolism, biodegradation and metabolism of exogenous substances, and energy metabolism. In addition, correlation analysis suggested that HSPA5 was negatively correlated with the content level of N2-(3-carboxypropionyl)-L-ornithine (N2-succinyl-L-ornithine). Western blot verification found that pazopanib significantly increased the expression levels of HSPA5, p-IRE1α, IRE1α, ATF4, ATF6, p-eIF2α, CHOP, LC3, Becline-1, Bax, and Caspase-3 proteins in mouse liver tissue or L02 cells, and decreased the expression levels of p-PI3K, p-AKT, and p-mTOR proteins in L02 cells.

[0155] Conclusion: Pazopanib can induce excessive autophagy by regulating HSPA5 expression and L-ornithine metabolism to mediate liver endoplasmic reticulum stress, thereby leading to liver cytotoxic effects.

[0156] Example 3

[0157] Study on the effect of pazopanib on regulating HSPA5-mediated apoptosis of L02 cells

[0158] Human liver L02 cells were cultured in vitro, and the HSPA5 gene in L02 cells was silenced by small interfering RNA (siRNA). Real-time fluorescence quantitative PCR and Western Blotting were used to test the transfection efficiency. Flow cytometry and Western Blot were used to detect the effects of ER stress inhibitors 4-PBA, L-ornithine and arginase inhibitor nor-NOHA on ER stress, apoptosis and autophagy in L02 cells or L02 cells transfected with siRNA HSPA5, as well as the protein expression levels of related proteins HSPA5, p-IRE1α, IRE1α, ATF4, ATF6, p-eIF2α, eIF2α, CHOP, LC3, Becline-1, Bax, Bcl-2, p-PI3K, PI3K, p-AKT, AKT, p-mTOR, and mTOR.

[0159] siRNA_HSPA5 and negative control siRNA_HSPA5_NC were synthesized by Shanghai Jima Pharmaceutical Technology Co., Ltd.

[0160]

[0161] siRNA transfection system

[0162]

[0163] L02 cell transfection

[0164] One day before transfection, 4×104L02 cells were seeded on a 24-well plate and the confluence of cells reached 90% within 24 hours. The siRNA freeze-dried powder was centrifuged instantaneously, and 20μM siRNA storage solution was prepared with RNase-free water. 1.25μL siRNA was added to 50μL Opti-MEM serum-free medium and mixed gently. 1μL Lipofectamine 3000 reagent was diluted with 50μL Opti-MEM serum-free medium, mixed gently, and left at room temperature for 5min. The Lipofectamine 3000 dilution and siRNA dilution were gently mixed and left at room temperature for 20min to form Lipofectamine / siRNA complex. 100μL Lipofectamine / siRNA complex was added to the culture plate containing cells and culture medium, and the cell culture plate was gently shaken back and forth in an 8-shaped pattern. After incubation in the incubator for 6h, new complete culture medium was replaced. After L02 cells were incubated in a CO2 incubator at 37°C for 48 h, the cells were collected and RNA and protein were extracted for expression detection.

[0165] Experimental Results

[0166] (1) Detection of 4-PBA, L-ornithine and nor-NOHA on pazopanib-mediated L02 cells

[0167] 4×10 4 L02 cells were seeded on a 24-well plate and the confluence of the cells reached 90% within 24 hours. Before the treatment of cells with pazopanib, the cells were pretreated with 0.5mM 4-PBA for 6 hours or 5mM L-ornithine for 24 hours, and then the L02 hepatocytes were intervened for 24 hours according to the above 20μM pazopanib treatment conditions. Subsequently, the cells were collected and the corresponding apoptosis levels and target protein expression levels of L02 hepatocytes were detected by flow cytometry and western blot, respectively.

[0168] (2) 4-PBA and silencing of HSPA5 attenuate pazopanib-mediated apoptosis of L02 cells

[0169] To observe whether endoplasmic reticulum stress affects pazopanib-mediated apoptosis of liver L02 cells, cells were pretreated with 0.5mM 4-PBA for 6h. At the same time, HSPA5 is mainly present in the endoplasmic reticulum. It is an important endoplasmic reticulum chaperone and signaling pathway regulator, and is involved in the occurrence and development of various diseases. In order to further explore the role of HSPA5 in pazopanib-mediated apoptosis of L02 cells, L02 cells were transfected with HSPA5 siRNA or siNC for 24h and then treated with pazopanib. siRNA was transfected in L02 cells. qPCR and Western blot results showed that compared with the siRNAHSPA5_NC group, the siRNAHSPA5 (#1, #2 and #3) group significantly inhibited the expression of HSPA5 ( Fig.26 AB), indicating the effectiveness of siRNA HSPA5 silencing, especially siRNA HSPA5_#1, which will be used in subsequent studies. Fig.26 As shown in C, flow cytometry results showed that the apoptosis rate of L02 cells pretreated with 4-PBA was significantly reduced compared with the pazopanib-treated group. The results suggest that 4-PBA can effectively attenuate pazopanib-mediated apoptosis of L02 cells. At the same time, silencing the expression of HSPA5 protein can significantly reduce the apoptosis rate of L02 cells compared with the pazopanib-treated group. The results show that silencing the expression of HSPA5 protein can significantly reduce the apoptosis of L02 hepatocytes induced by pazopanib.

[0170] (3) 4-PBA and silencing HSPA5 inhibit pazopanib-induced ER stress protein expression

[0171] like Fig. 27As shown in the figure, Western blot analysis showed that 4-PBA and silencing of HSPA5 also had significant inhibitory effects on the phosphorylation levels of endoplasmic reticulum stress-related proteins IRE1α and eIF2α, and the protein expressions of ATF4, ATF6, and CHOP. The results suggest that 4-PBA and silencing of HSPA5 may weaken pazopanib-mediated endoplasmic reticulum stress in L02 hepatocytes.

[0172] (4) 4-PBA and silencing HSPA5 inhibited pazopanib-induced autophagy protein expression and promoted PI3K / Akt / mTOR expression

[0173] In order to study the effects of 4-PBA and silencing HSPA5 on the expression of autophagy proteins induced by pazopanib and the expression of PI3K / Akt / mTOR signaling pathway, this example further used western blotting to detect L02 cells treated with 4-PBA and silencing HSPA5. The results showed that compared with the pazopanib group, the expression levels of LC3, Beclin-1 and Bax proteins in the 4-PBA and silencing HSPA5 groups of L02 cells were significantly reduced, while the expression level of Bcl-2 protein was significantly increased; furthermore, this example further found that after 4-PBA and silencing HSPA5 treatment, the phosphorylation levels of PI3K, Akt, and mTOR proteins in L02 cells were significantly increased, such as Fig.28 The results showed that 4-PBA and silencing of HSPA5 could mediate the activation of PI3K / Akt / mTOR signaling pathway and reduce pazopanib-induced cell autophagy.

[0174] (5) Inhibition of ornithine metabolism pathway weakens the apoptosis and autophagy effects of silencing HSPA5 on L02 cells

[0175] L-Ornithine is an intermediate metabolite of arginine biosynthesis in the urea cycle, which promotes the urea cycle, maintains the metabolic balance of NH3 in the body, and plays a role in protecting the liver. This embodiment further uses the arginase inhibitor nor-NOHA to regulate the ornithine metabolism level. Fig.29As shown in A, the results of flow cytometry experiments showed that compared with the pazopanib-treated group, the apoptosis rate of L02 cells in the L-ornithine-treated group and the HSPA5-silencing group was significantly reduced, while compared with the HSPA5-silencing group, the apoptosis rate of L02 cells in the HSPA5+nor-NOHA-silencing group was significantly increased. At the same time, this example explores the effects of L-ornithine supplementation and inhibition of ornithine metabolic pathways on L02 cell apoptosis, autophagy, and the expression of proteins related to the PI3K / Akt / mTOR signaling pathway. The results showed that after L02 cells were treated with L-ornithine, the expression levels of endoplasmic reticulum stress-related proteins HSPA5, ATF4, CHOP and autophagy and apoptosis-related proteins LC3, Beclin-1, and Caspase-3 were significantly reduced, and the phosphorylation levels of PI3K, Akt, and mTOR proteins were significantly increased. However, compared with the HSPA5-silencing group, the nor-NOHA group showed the opposite expression level, as shown in Figure 2. Fig.29 As shown in B. This suggests that knocking down HSPA5 combined with the arginase inhibitor nor-NOHA may jointly inhibit pazopanib-induced hepatocyte apoptosis and autophagy.

[0176] In summary, (1) the study found that 4-PBA, silencing HSPA5 and exogenous L-ornithine supplementation could significantly inhibit pazopanib-induced ER stress, apoptosis and autophagy in L02 cells; (2) the study showed that 4-PBA, silencing HSPA5 and exogenous L-ornithine supplementation significantly reduced the expression levels of ER stress, apoptosis and autophagy-related proteins and promoted the activation of the PI3K / AKT / mTOR signaling pathway; (3) the study showed that the arginase inhibitor nor-NOHA reversed the silencing of HSPA5 to inhibit pazopanib-mediated hepatocyte apoptosis, increased autophagy and the activation level of the PI3K / Akt / mTOR signaling pathway.

[0177] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can easily think of various equivalent modifications or replacements within the technical scope disclosed by the present invention, and these modifications or replacements should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be based on the protection scope of the claims.

Claims

1. Use of an endoplasmic reticulum stress inhibitor in the preparation of a drug for eliminating or alleviating hepatotoxicity caused by pazopanib.

2. The use according to claim 1, It is characterized in that The endoplasmic reticulum stress inhibitor includes 4-PBA.

3. Use of endoplasmic reticulum stress marker protein silencing agents in the preparation of drugs for eliminating or alleviating hepatotoxicity caused by pazopanib.

4. The use according to claim 3, It is characterized in that The endoplasmic reticulum stress marker protein includes the endoplasmic reticulum stress marker protein HSPA5.

5. Use of L-ornithine metabolic regulators in the preparation of drugs for eliminating or alleviating hepatotoxicity caused by pazopanib.

6. The use according to claim 5, It is characterized in that The L-ornithine metabolism regulator includes the arginase inhibitor nor-NOHA.

7. Use of arginase inhibitor nor-NOHA and HSPA5 silencer in the preparation of drugs for eliminating or reducing hepatotoxicity caused by pazopanib.

8. Use of L-ornithine supplement in the preparation of a medicament for eliminating or alleviating hepatotoxicity caused by pazopanib.

9. Application of endoplasmic reticulum stress inhibitors and pazopanib in the preparation of drugs for the treatment of renal cell carcinoma.

10. Application of endoplasmic reticulum stress marker protein silencing agent and pazopanib in the preparation of therapeutic drugs for renal cell carcinoma.